Two-stage design and 'forced bioequivalence' [Two-Stage / GS Designs]

posted by Yura – Belarus, 2018-06-07 12:24 (2570 d 04:57 ago) – Posting: # 18859
Views: 6,465

Hi Mikalai,
'forced bioequivalence' - it's not from "that opera".
If you took for 2х2х2 n = 120 for CL AUCt (90-111.11 - with narrow therapeutic index), CV = 16.5% and recommended GMR = 97.5%, while in calculation (in R) for 2х2х4 you get n = 30.
The sample size is twice as high as possible, which is not ethical - to expose an unknown effect of the test drug to more people than necessary.
If I understand correctly, that's it 'forced bioequivalence'
regards

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
35 visitors (0 registered, 35 guests [including 11 identified bots]).
Forum time: 17:22 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5